< Terug naar vorige pagina

Publicatie

De cellulaire en moleculaire architectuur van ischemische beroerte- en ECMO-klonters: Nieuwe inzichten in de pathofysiologie en therapie door middel van histologische studies.

Boek - Dissertatie

Acute ischemic stroke is one of the leading causes for mortality and long-term disability worldwide. This is caused by blood thrombi that occlude cerebral blood arteries, leading to an impaired blood flow and irreversible damage of the associated brain tissue. The morbidity of ischemic stroke will continue to rise as age is one of the most substantiated risk factors. The socio-economic burden of stroke is in strong contrast with the limited treatment options. Currently, only one pharmacological/thrombolytic agent, tissue plasminogen activator (t-PA), has been approved. However, t-PA can only be administered in a limited time window of 4.5 hours after stroke onset due to the risk of intracranial hemorrhage when treatment is postponed. As a consequence, t-PA can only be used in less than half of the patients. Most remarkably, t-PA results in recanalization in less than half of the patients that are treated whereas factors contributing to this 't-PA resistance' are not well understood. Nowadays, thrombectomy can be used in patients that fail standard thrombolytic therapy to mechanically remove blood thrombi from the cerebral arteries. This technique presents itself with the possibility to analyze the retrieved thrombi ex vivo. Indeed, this project aims to unravel both clinical (e.g. functional outcome) and fundamental (e.g. clot composition) aspects of stroke by analyzing cerebral thrombi from patients.
Toegankelijkheid:Open